|
gptkbp:instanceOf
|
gptkb:nerve_agent
|
|
gptkbp:absorptionRoute
|
gptkb:skin
inhalation
|
|
gptkbp:aroma
|
odorless
|
|
gptkbp:CASRegistryNumber
|
varies by agent
|
|
gptkbp:color
|
colorless
|
|
gptkbp:developedBy
|
gptkb:United_Kingdom
|
|
gptkbp:effect
|
respiratory failure
convulsions
muscle paralysis
|
|
gptkbp:firstSynthesized
|
1950s
|
|
gptkbp:mechanismOfAction
|
gptkb:acetylcholinesterase_inhibitor
|
|
gptkbp:notableMember
|
gptkb:VE
gptkb:VM
gptkb:VX
VG
VS
|
|
gptkbp:persistenceMechanism
|
high
|
|
gptkbp:physicalState
|
liquid at room temperature
|
|
gptkbp:prohibits
|
gptkb:Chemical_Weapons_Convention
|
|
gptkbp:relatedTo
|
G-series nerve agents
|
|
gptkbp:solubility
|
slightly soluble in water
soluble in organic solvents
|
|
gptkbp:subclassOf
|
gptkb:organophosphate_compound
|
|
gptkbp:toxicity
|
extremely high
|
|
gptkbp:treatment
|
gptkb:benzodiazepines
gptkb:pralidoxime
atropine
|
|
gptkbp:usedIn
|
chemical warfare
|
|
gptkbp:bfsParent
|
gptkb:O-ethyl_S-[2-(diisopropylamino)ethyl]_methylphosphonothioate
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
V-series nerve agents
|